Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ofelia Balta

Internal Medicine Sylva, NC Medical Doctor

NPI 1912980178 CMS profile 177217

98 Cope Creek Rd Ste A-B, Sylva, NC 28779

Open in the dashboard

General payments

$9,238

611 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ofelia Balta of Sylva, NC is reported in the CMS Open Payments database as having received $9,238 across 611 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $502 27
2024 General $1,132 59
2023 General $1,446 83
2022 General $1,378 90
2021 General $1,061 68
2020 General $1,917 125
2019 General $1,801 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ofelia Balta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ofelia Balta were reported at $502. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ofelia Balta Internal Medicine median Middle half National median
2019 $1,801 $159 $48–$570 $163
2020 $1,917 $119 $33–$402 $114
2021 $1,061 $135 $37–$521 $132
2022 $1,378 $141 $42–$496 $149
2023 $1,446 $149 $45–$519 $160
2024 $1,132 $154 $47–$537 $164
2025 $502 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,166 71 payments
  2. Novo Nordisk Inc $1,140 86 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $804 34 payments
  4. Amgen Inc. $610 39 payments
  5. Pfizer Inc. $563 48 payments
  6. Lilly USA, LLC $538 33 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $505 38 payments
  8. AstraZeneca Pharmaceuticals LP $442 30 payments
  9. Allergan Inc. $421 30 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $383 43 payments
  11. Other $2,665 159 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,205 605 payments
  2. Education $33 6 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $804 34 payments
  2. Ozempic $783 59 payments
  3. RYBELSUS $657 47 payments
  4. VRAYLAR Neuroscience $557 32 payments
  5. Repatha $355 23 payments
  6. JARDIANCE $342 28 payments
  7. VRAYLAR Neuroscience $326 18 payments
  8. FARXIGA $319 21 payments
  9. TRELEGY ELLIPTA $272 18 payments
  10. REXULTI $252 11 payments
  11. Other $7,808 556 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

4,696

Median for Internal Medicine: 777

Drug cost

$368,554

Median for Internal Medicine: $73,373

Branded share of claims

19.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 27 $55,346
Jardiance Empagliflozin Brand 48 $47,033
Mounjaro Tirzepatide Brand 32 $43,037
Creon Lipase/Protease/Amylase Brand 13 $34,670
Eliquis Apixaban Brand 50 $30,950
Januvia Sitagliptin Phosphate Brand 31 $23,032
Repatha Sureclick Evolocumab Brand 28 $15,732
Xarelto Rivaroxaban Brand 11 $14,542
Synjardy Empagliflozin/Metformin Hcl Brand 20 $12,903
Glyxambi Empagliflozin/Linagliptin Brand 13 $12,214

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$692,333

Of which drugs: $471,810

Medicare patients

510

Average age 74

Services billed

5,630

372 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 44%
Depression 27%
Diabetes 25%
Chronic kidney disease 25%
Osteoporosis 24%
Ischemic heart disease 17%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 44 44 $749
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 432 $316
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 20 105 $97
Injection, ceftriaxone sodium, per 250 mg J0696 Office 50 262 $88
Injection, ketorolac tromethamine, per 15 mg J1885 Office 30 80 $37
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 30 39 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $197
$197 — —
VRAYLAR
  • AbbVie, Inc. $136
$136 — —
RYBELSUS
  • Novo Nordisk Inc $84
$84 — —
Ozempic
  • Novo Nordisk Inc $84
$84 27 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

611 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record